Dates: June 6-7, 2023 | CAR T Cell Therapy and Advances in Cellular Engineering

In this clinical update, we look at recent advances in two clinical-stage gene-editing programmes. Editas Medicine's sickle cell disease candidate...

Founded in 2011, Caribou Biosciences is developing novel allogeneic CAR-T cell and CAR-natural killer cell therapies to treat cancer. The UC Berkeley...

In this update, we summarise the two ongoing gene-editing clinical trials for renal cell carcinoma, which is the most common form of kidney cancer...

Last week, Allogene Therapeutics announced the publication of data from the Phase 1 UNIVERSAL trial of ALLO-715, a TALEN-engineered CAR-T candidate...

Researchers in the U.S. recently shed much needed light on the molecular mechanisms underpinning T cell exhaustion, revealing an epigenetic regulator...

This week's update features Iovance Biotherapeutics' new cancer immunotherapy candidate IOV-4001 that was recently cleared for clinical trial...

Intellia Therapeutics recently announced that the first patient had been dosed in its Phase 1/2a CRISPR trial for acute myleoid leukaemia (AML). The...